News

Acute myeloid leukaemia (AML) is one of the most aggressive and complex blood cancers. Despite significant advances in blood cancer treatment, many people diagnosed with AML, particularly older adults who are not fit enough for intensive chemotherapy, continue to face limited treatment options and have a high risk of relapse.

Clinical trial research is changing that. Thanks to advances in genetics, precision medicine and innovative clinical trial design, scientists are gaining a much deeper understanding of AML and developing more personalised ways to treat it. One of the most exciting examples is the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM28 ADAPT Platform Trial, supported by the Medical Research Future Fund (MRFF), and an Australian-led study designed to continually improve treatment. By adapting as new discoveries emerge, the trial has the potential to bring better treatments to patients faster, improve outcomes and address some of the biggest challenges in AML care.

Continued research of this scale is only possible through ongoing financial support. Every donation helps drive the discoveries that are shaping the future of AML treatment and brining hope to patients and their families.

Support Research, Save Lives

Understanding AML is Changing the way we Treat it

AML has long been recognised as one of the most challenging blood cancers to treat because no two cases are exactly alike.

Advances in genomic research have shown that AML is driven by a wide range of genetic mutations, each influencing how the disease develops, how it responds to treatment and the likelihood of relapse. This growing understanding has fundamentally changed the way researchers think about AML.  Modern research is focused on tailoring treatment to the unique biology of each patient’s disease.

The challenge is that AML can change over time. Cancer cells evolve, new mutations emerge and treatments that initially worked may eventually become less effective, and research needs to be just as adaptable.

Research to Improve AML Outcomes

The AMLM28 ADAPT Platform has been specifically designed to meet this challenge.

Targeting older adults with AML who are unsuitable for intensive chemotherapy, the trial focuses on patients receiving current standard of care.

What makes this trial different is its innovative platform design.

Rather than launch a completely new trial every time researchers want to test a new promising treatment, the platform allows new research questions to be addressed as scientific knowledge grows, allowing researchers to evaluate:

• New treatment combinations
• Whether treatment can be reduced for patients in long term remission
• Measurable residual disease (MRD) to detect any tiny amounts of remaining leukaemia
• Better support care strategies to improve quality of life

This flexible and targeted approach has the potential to accelerate discoveries while giving more patients access to cutting-edge therapies.

AMLM28 ADAPT Chief Investigator Professor Andrew Wei

AMLM28 ADAPT Co-Chief Investigator Dr Chyn Chua

Why this Research Matters – and Why Your Support is Essential

Every improvement in AML treatment begins with research.

Platforms like AMLM28 ADAPT represent the future of cancer research as they allow scientists to respond quickly as new discoveries emerge. Instead of waiting to build new studies from scratch, researchers can efficiently test promising therapies within an established framework – bringing better treatments to patients sooner.

But research programs require substantial funding. Your donation helps support the infrastructure that makes innovative clinical trials possible – from genetic testing and  laboratory research, to patient monitoring, data collection, and collaboration.

By supporting research, you will help researchers develop more personalised treatments, reduce relapse, improve survival and move closer to a future where a person diagnosed with AML has access to therapies tailored to their disease.

Support Research, Save Lives